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OBJECTIVE — To evaluate the safety and efﬁcacy of ingested human recombinant interfer-
on- (hrIFN-) for preservation of -cell function in young patients with recent-onset type 1
diabetes.
RESEARCH DESIGN AND METHODS — Subjects aged 3–25 years in whom type 1
diabeteswasdiagnosedwithin6weeksofenrollmentwererandomlyassignedtoreceiveingested
hrIFN- at 5,000 or 30,000 units or placebo once daily for 1 year. The primary outcome was
change in C-peptide secretion after a mixed meal.
RESULTS — Individuals in the placebo group (n  30) lost 56  29% of their C-peptide
secretion from 0 to 12 months, expressed as area under the curve (AUC) in response to a mixed
meal.Incontrast,childrentreatedwithhrIFN-lost2954and4835%(for5,000[n27]
and30,000units[n31],respectively,P0.028,ANOVAadjustedforage,baselineC-peptide
AUC, and study site). Bonferroni post hoc analyses for placebo versus 5,000 units and placebo
versus 30,000 units demonstrated that the overall trend was determined by the 5,000-unit
treatment group. Adverse events occurred at similar rates in all treatment groups.
CONCLUSIONS — Ingested hrIFN- was safe at the doses used. Patients in the 5,000-unit
hrIFN- treatment group maintained more -cell function 1 year after study enrollment than
individuals in the placebo group, whereas this effect was not observed in patients who received
30,000 units hrIFN-. Further studies of low-dose ingested hrIFN- in new-onset type 1
diabetes are needed to conﬁrm this effect.
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R
esidual -cell function was shown
to correlate with decreased compli-
cation rates in the Diabetes Control
and Complications Trial (1). As a result,
preservation of -cell function is an im-
portant treatment goal in patients with
type 1 diabetes. Over the past 25 years,
multiple clinical trials attempted to pre-
vent progressive -cell destruction after
the diagnosis of type 1 diabetes using im-
munosuppressive or immunomodulatory
agents such as cyclosporin (2,3), cyclo-
sporin in combination with bromocrip-
tine (4), azathioprine with or without
glucocorticoids (5,6), nicotinamide with
orwithoutglucocorticoids(7,8),andpar-
enteralinterferon-(IFN-)(9).Morere-
cent intervention trials used monoclonal
antibody–based therapies such as ritux-
imab (anti-CD-20) (clinical trial reg. no.
NCT00279205), daclizumab (anti-
CD25) in combination with mycopheno-
late mofetil (clinical trial reg. no.
NCT00100178), anti-CD3 (10–12), and
GAD (13). Although several studies are
still ongoing and thus the results are
pending, trials of anti-CD3 antibodies
and GAD have demonstrated delayed de-
cline of endogenous insulin secretion.
However,noneoftheseinterventiontrials
have yet been translated into common
clinical practice for two reasons: 1) the
-cell protective effect has been tempo-
rary, and 2) some of the agents available
were associated with unacceptable side
effects, such as impairment of renal func-
tion in the case of calcineurin inhibitors.
Theoriginalobservationthatingested
type 1 interferon has an immunomodula-
tory effect was made in mice with chronic
relapsing experimental autoimmune en-
cephalomyelitis (14). Subsequently, a
phase I trial demonstrated that 10,000–
30,000 but not 100,000 units ingested
IFN- act as a biological response modi-
ﬁer without apparent toxicity in humans
with multiple sclerosis (15), and a phase
IItrialsuggestedthat10,000unitsmaybe
moreclinicallyeffectivethan30,000units
(16). The mechanism of action remains
unclear. It is thought that ingested inter-
feron, which is acid stable and therefore
resists gastric digestion, binds to high-
afﬁnity receptors in the gut-associated
lymphoid tissue where it transduces its
signal. Serum levels do not change nor
do other protein markers of interferon
absorption (e.g., 2-microglobulin, ne-
opterin, and 2-5A synthetase) (17).
A decade ago, ingested INF- was re-
ported to modify the onset of autoim-
mune diabetes in a commonly used
animal model, the nonobese diabetic
(NOD) mouse. Adoptive transfer of un-
stimulated splenocytes secreting interleu-
kin (IL)-4 and IL-10 from mouse IFN-–
fed donors suppressed spontaneous
diabetesinrecipients,thusdemonstrating
the presence of ingested IFN-–activated
regulatory splenic cell populations that
work via increased IL-4 or IL-10 produc-
tion(18).Asmall,open-labelpilotproject
in 10 children with recently diagnosed
type 1 diabetes supported the safety of
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ﬁnding (19). The current study is the ﬁrst
randomized, controlled trial testing the
safety and efﬁcacy of ingested human re-
combinant (hr) IFN- to preserve -cell
function in young patients with recent-
onset type 1 diabetes.
RESEARCH DESIGN AND
METHODS— The present clinical
trial was designed as a prospective, ran-
domized, placebo-controlled, double-
blind, multicenter, parallel-group study.
Eligible subjects were between 3 and 25
years old, had a diagnosis of type 1 diabe-
tes by standard clinical criteria within the
preceding 6 weeks, and had no other
medically signiﬁcant concurrent illness.
Study approval was obtained from the in-
stitutional review boards at each partici-
pating center (a list of centers is found in
an online appendix, available at http://
care.diabetesjournals.org/cgi/content/full/
dc08-2029/DC1). Written informed con-
sent was obtained from subjects or their
guardians before enrollment, and minors
provided written or verbal assent.
A total of 128 patients were enrolled
at the ﬁve participating centers (54 at the
National Institutes of Health [NIH] and
74 at other sites) and were randomly as-
signed by block centrally with no stratiﬁ-
cation to one of the following three
treatment arms: placebo, 5,000 units
hrIFN-, or 30,000 units hrIFN-.A t
screening and every 3 months thereafter,
patients underwent a mixed-meal study
(Boost High Protein, 7 ml/kg, maximum
400 ml). Blood samples were obtained at
–10, 0, 30, 60, 90, and 120 min.
Interferon preparation and
administration
Medications were prepared at each cen-
ter’s pharmacy as either 5,000 or
30,000 units hrIFN-. Roferon (Roche)
was diluted in saline with 6 mg human
serum albumin (HSA), and placebo was
preparedassalinealonewith6mgHSA.
The initial dose of medication or pla-
cebo was administered under supervi-
sion. Patients received monthly supplies of
vials containing frozen hrIFN- or placebo
and were instructed to store these vials in
the freezer. Each night, one vial was trans-
ferredtotherefrigeratorandthawed.In the
morning before breakfast, the content
of each vial was swallowed with at least
150 ml of water. Neither taste nor gen-
eral appearance differed between the
placebo and interferon-containing sa-
line solutions.
Biochemical measurements
NIH study participants’ C-peptide levels
were determined with a competitive
chemiluminescence assay at the NIH
Clinical Center laboratory. The normal
range in healthy, nondiabetic individuals
is 0.3–1.3 nmol/l (0.9–4.0 ng/ml) with
an intra-assay precision of 3.4% at 1.44
nmol/l (4.34 ng/ml) and an interassay
precision of 7.7 and 8.3% at 0.37 nmol/l
(1.12 ng/ml) and 1.98 nmol/l (5.94 ng/
ml), respectively. The lower limit of de-
tectionwas0.17(0.5ng/ml).Allnon-NIH
participants’ C-peptide concentrations
were determined with a radioimmunoas-
say(Linco),whichhadanintra-assaypre-
cision of 3.4–6.4% and an interassay
precision of 2.4–9.3%. The standard
curve ranged from 0.03 to 1.67 nmol/l
(0.1 to 5 ng/ml) and the lower limit of
detection was 0.03 nmol/l (0.1 ng/ml).
Serumglucosemeasurementsweredeter-
mined using the glucose oxidase method
(intra-assay CV 2.9% at 2.4 mmol/l [44
mg/dl]and0.4%at22.1mmol/l[397mg/
dl] and interassay CV 3.9% at 2.4 mmol/l
[44 mg/dl] and 1.2% at 22.1 mmol/l [397
mg/dl]). A1C was determined by high-
performance liquid chromatography (in-
tra-assay CV 0.58% for normal A1C and
0.42% for elevated A1C; interassay CV
1.3% for normal A1C and 0.93% for ele-
vated A1C).
Efﬁcacy assessments
The primary outcome was the change in
meal-stimulatedC-peptideareaunderthe
curve (AUC) from the beginning to the
end of the study. Because different C-
peptide assays were used at the NIH ver-
sus the other participating centers,
changes in C-peptide secretion are re-
ported as percent change from baseline as
well as absolute change.
Safety assessments
Safety was assessed by physical examina-
tions, clinical laboratory measurements,
anddocumentationofadverseevents.Ev-
ery 6 months during the study, a data
safety and monitoring board reviewed all
patients’ data in an unblinded fashion.
Statistical analysis
C-peptide AUC following the mixed-meal
test was calculated using the trapezoidal
method. Repeated-measures mixed models
(ProcMixSAS)wereusedtoassessthepro-
portional differences in C-peptide AUC
over time among treatment groups. All
Figure 1—Patient ﬂow diagram. ANA, anti-nuclear antibodies.
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treatment, time, baseline C-peptide AUC,
andinteractionoftreatmentandtime.Mod-
els that assessed C-peptide differences were
also adjusted by site because two different
C-peptide assays were used. An autoregres-
sive covariance structure was used, and
Bonferronicorrectionwasusedformultiple
pairwise comparisons. The least-square
means were estimated at each time point.
Sensitivity analyses compared baseline dif-
ferencesinC-peptidelevelsbystudysite,by
theassayused,andbycompletersamongall
three arms of the study. A completer was
deﬁned as a patient who completed at least
9 months follow-up.
In addition to the repeated-measures
analyses, the absolute and relative
changes from baseline to 12 months were
assessed. The absolute difference of C-
peptide AUC was deﬁned as the AUC at
screening minus the AUC at 12 months.
The proportional loss of C-peptide AUC
was calculated by dividing the absolute
difference by C-peptide AUC at screen-
ing. Pearson 
2 tests and ANOVAs were
used to assess the proportional loss of C-
peptide AUC among the three arms of the
study (placebo, 5,000 units hrIFN-,o r
30,000 units hrIFN-). Secondary analy-
ses included differences in A1C and insu-
lindose,overtimeandbetweentreatment
groups.
Data are presented as means  SD.
Statistical signiﬁcance was assigned for
P  0.05. Data processing and statistical
evaluations were completed using SAS
(version 9.1, SAS Institute, Cary, NC).
RESULTS— Of 128 subjects enrolled
in the study, 107 received at least one
dose of study drug, and 93 completed the
follow-up (Fig. 1). Five patients who
completed the study were excluded from
the ﬁnal analysis because they changed
study centers (and thus C-peptide assays)
during the study period. Thus, a total of
88 subjects generated data for the ﬁnal
analysis.
Baseline characteristics of subjects in-
cluded in the ﬁnal analysis are shown in
Table 1. Sensitivity analyses showed no
signiﬁcant differences between baseline
characteristics of noncompleters and
completers.
Safety
Three serious adverse events (SAEs) oc-
curred during the study. An 18-year-old
male patient developed Staphylococcus
septicemia during his 9th month of treat-
ment with 30,000 units hrIFN-. His
subsequent clinical course was compli-
cated by multiple peripheral emboli, and
he required prolonged hospitalization.
The patient recovered fully but hrIFN-
was discontinued. One placebo-treated
patient developed medulloblastoma, and
another placebo-treated patient devel-
oped gastroenteritis resulting in diabetic
ketoacidosisrequiringhospitalization.All
SAEs and adverse events were reviewed
by the data safety and monitoring board,
and no SAE was considered to be related
to therapy.
There was no difference in the occur-
rence of adverse events among the three
treatment groups. During the study, sub-
jectshadmeansSDof2.12.4,1.6
2.0, and 2.1  2.1 adverse events each in
the placebo, 5,000-unit hrIFN-, and
30,000-unit hrIFN- groups, respec-
tively. Other than the SAEs, all adverse
events were rated as mild to moderate
(grades 1 or 2). A summary of adverse
events is found in Table 2.
C-peptide secretion
C-peptide AUC at screening was lower in
subjectsevaluatedattheNIHversusthose
evaluated at other study sites (1.5  0.7
mmol/l for NIH vs. 2.0  1.2 mmol/l for
allothersites,P0.02).However,mixed
models revealed no signiﬁcant effect of
study site for either absolute or relative
change in C-peptide AUC from 0 to 12
months; hence, subjects from all sites
werecombinedforanalysisoftheprimary
outcome.
Figure 2 shows the decline in mixed-
meal stimulated C-peptide AUC over the
period of follow-up. Mixed-model analy-
sis revealed a signiﬁcant effect of treat-
ment for percent loss (P  0.046) (Fig.
2A) and near signiﬁcance for absolute
change(P0.064)(Fig.2B)inC-peptide
AUC. Treatment by time interactions in
the repeated-measures analysis was not
statistically signiﬁcant (percent loss P 
0.116; absolute change P  0.144). Sub-
jects treated with hrIFN- had less per-
cent loss of C-peptide at 12 months
relative to screening compared with pla-
cebo-treated control subjects (56  29,
29  54, and 48  35% for placebo,
5,000 units, and 30,000 units, respec-
tively, P  0.028, ANOVA adjusted for
age, study site, and baseline C-peptide
AUC). Bonferroni post hoc analyses for
placebo versus 5,000 units and placebo
versus 30,000 units demonstrated that
the overall trend was led by the 5,000-
unit treatment group (placebo vs. 5,000
units P  0.017; placebo vs. 30,000 units
P  0.599).
Age was a signiﬁcant predictor of
C-peptide loss, with older patients los-
ing less C-peptide secretion (P 
Table 1—Baseline patient characteristics of 88 patients included in the ﬁnal analysis
Placebo 5,000 units 30,000 units P
n 30 27 31
Study site 0.56
NIH 16 (53) 11 (41) 13 (42)
Non-NIH 14 (47) 16 (59) 18 (58)
Age (years) 10.8  4.8 10.5  5.1 9.9  4.4 0.78
Sex 0.88
Male 17 (57) 17 (63) 19 (61)
Female 13 (43) 10 (37) 12 (39)
Ethnicity 0.57
Caucasian 25 (83) 26 (96) 28 (90)
Asian 3 (10) 1 (4) 1 (3)
Hispanic 2 (7) 0 (0) 2 (6)
Insulin dose (units   kg
1   day
1) 0.43  0.27 0.46  0.22 0.43  0.19 0.89
Diabetic ketoacidosis at diagnosis 4 (13) 4 (15) 4 (13) 1.00
A1C (%) 8.2  1.6 8.0  1.7 8.2  1.2 0.86
Positive GAD65 17 (77) 14 (87) 14 (74) 0.66
Fasting C-peptide (nmol/l) 0.46  0.33 0.39  0.25 0.50  0.47 0.53
Screening C-peptide AUC (nmol  
l
1   120 min
1) 1.77  1.11 1.81  0.83 1.70  1.02 0.91
Screening glucose AUC (mmol  
l
1   120 min
1) 24.1  8.2 21.9  5.8 22.9  6.2 0.46
DataaremeansSDorn(%).PvaluesarebasedonPearson’s
2test,Fisher’sexacttest,Kruskal-Wallistest,
or ANOVA as appropriate.
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cluding age as a dichotomous variable
(age 10 years [n  47] vs. age 10
years [n  41]) did not reveal a signiﬁ-
cant age by treatment interaction for ei-
ther percent (P  0.66) or absolute
change (P  0.63) in C-peptide AUC
from 0 to 12 months.
Secondary study objectives
There was no difference among treatment
groups for the decline in A1C from
screening to 12 months (placebo 0.7 
1.6%, 5,000 units hrIFN- 0.9  2.1%,
and 30,000 units hrIFN- 0.8  1.3%,
P  0.46) (Fig. 2C). There was also no
signiﬁcant difference between groups for
rise in insulin dose from screening to 12
months (placebo 0.20 0.28 units  kg
1 
day
1, 5,000 units hrIFN- 0.10  0.26
units   kg
1   day
1, and 30,000 units
hrIFN-0.140.26units kg
1 day
1,
P  0.71) (Fig. 2D).
CONCLUSIONS — Greater residual
-cell function lowers the risk of devel-
oping nephropathy, neuropathy, and
retinopathy and markedly reduces the
risk of hypoglycemia (1). As a result,
preservationofasmuchresidualendog-
enous insulin secretion as possible is
predicted to have a major impact on
health outcomes in patients with type 1
diabetes.Inthisstudy,weobservedthat
ingested hrIFN- was safe in children
with new-onset type 1 diabetes. This
ﬁnding is of crucial importance because
we tested a novel treatment for children
Figure 2—Changes over time in 88 subjects with new-onset type 1 diabetes who completed 12 months of treatment with either once-daily placebo
(n  30) or 5,000 units (n  27) or 30,000 units (n  31) ingested hrIFN-. A: Percent change in C-peptide AUC after a mixed-meal test. B:
C-peptide AUC after a mixed-meal test. C: A1C. D: Insulin dose.
Table 2—Adverse events by treatment group
Treatment group
30,000 units 5,000 units Placebo
n 44 40 44
Infection (viral) 14 (31.8) 9 (22.5) 9 (20.5)
Infection (bacterial) 7 (20.5) 2 (12.5) 4 (22.7)
Infection (upper airway) 24 (54.5) 20 (50.0) 30 (68.2)
Dermatologic/skin 2 (4.5) 2 (5.0) 3 (6.8)
Gastrointestinal 5 (11.4) 3 (7.5) 4 (9.1)
Pancreatic/endocrine 2 (4.5) 6 (15.0) 2 (4.5)
Bleeding 2 (4.5) 0 (0) 0 (0)
Neurological 1 (2.3) 2 (5.0) 5 (11.4)
Allergy/immunology 8 (18.2) 6 (15.0) 3 (6.8)
Cancer 0 (0) 0 (0) 1 (2.3)
Musculoskeletal 0 (0) 1 (2.5) 4 (9.1)
Metabolic/laboratory 20 (45.5) 9 (22.5) 8 (18.2)
Data are n (%).
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well with insulin alone. Thus, the ac-
ceptable safety margin for any interven-
tion in this population is very small.
Some safety concerns had arisen due to
reports about high-dose interferon
treatment in adult patients with hepati-
tis who developed new-onset type 1 di-
abetes (20). However, the present
diabetes treatment and the hepatitis
therapy differ by an approximate factor
of10,000regardingtheinterferondose.
Further concern could be based on the
role of IFN- as an initiator in the de-
velopment of the autoimmune diabetes,
which has only been shown in rodents
(21).
In addition to the good safety proﬁle,
we found that children who had received
the 5,000-unit hrIFN- dose lost less C-
peptide (expressed as percent loss) from
study entry to 12 months. There was no
signiﬁcant treatment by time interaction
observed on repeated-measures analysis,
suggesting that, although the groups di-
verged early in the study, the rate of C-
peptidelosswasroughlyequalamongthe
groups after 3 months. This ﬁnding is
consistent with those for other therapies
for C-peptide preservation in type 1 dia-
betes, including anti-CD3 and GAD
(11,13).
The superiority of the 5,000-unit
dose of hrIFN- over the 30,000-unit
doseisconsistentwithhumanandanimal
data supporting greater efﬁcacy of lower
doses of ingested interferon in autoim-
mune disease (15,16,22). These ﬁndings
suggest that ingested interferon may have
a hormetic dose-response relationship
(i.e., generally favorable biological re-
sponses to low exposures with the oppo-
site effect at high doses). The biological
basisofsuchbiphasicdose-responserela-
tionships is poorly understood, but they
appear to be common in immunology
(23).
Although no statistically signiﬁcant
differences were found among treatment
groups for secondary outcomes, includ-
ing A1C and insulin dose, the general
trend in these parameters supported the
primary outcome. That is, patients in the
5,000-unit hrIFN- group had smaller
increasesininsulindose,accompaniedby
greater declines in A1C.
This study is limited by several im-
portant drawbacks. First, different C-
peptideassayswereusedforNIHsubjects
versussubjectsatallotherstudysites.We
attempted to compensate for this limita-
tion by determining relative loss of C-
peptide secretion rather than using the
absolute C-peptide measurements. In ad-
dition, we excluded from the analysis ﬁve
subjects who changed study sites, for
whom the 12-month C-peptide results
could not be compared with the baseline
values because of the different assays
used. The validity of performing a com-
bined analysis for primary outcome using
subjectsfromallsitesissupportedbysep-
arate analyses for NIH and non-NIH sub-
jects showing similar trends in C-peptide
secretion(datanotshown)andbymixed-
model analyses that demonstrated no sta-
tistically signiﬁcant differences by study
site.
A second signiﬁcant study drawback
was the difference in chronic and acute
blood glucose management among study
participants. Primary diabetes care was
provided by local pediatric endocrinolo-
gists. Thus, some patients may have
beneﬁted from more intense insulin
therapy and reduced glucotoxicity,
which by itself may have inﬂuenced
-cell preservation. However, there
were no differences in A1C or insulin
pump use among the three treatment
groups, suggesting that differences in
chronic blood glucose control were un-
likely to have affected the study out-
come. Most clinical trials in the ﬁeld of
type 1 diabetes are challenged by the
differencesinacutebloodglucoselevels
at the time of provocative testing. De-
spite attempts to perform the mixed
meals under reproducible conditions,
blood glucose levels differed from one
test to another. However, because this
trial was performed in a randomized
fashion, we believe that this factor did
not play an important role regarding
our main outcomes.
Although intent-to-treat analysis was
not performed in this study, 87% of sub-
jects who received even a single dose of
hrIFN- completed the study. In addi-
tion, sensitivity analyses did not demon-
strate any signiﬁcant differences between
baselinevariablesinsubjectswhodidver-
sus did not complete the study. All but
two subjects (one patient in the placebo
group who developed a brain tumor and
another patient in the 30,000-unit
hrIFN- group who developed Staphyloc-
cocus sepsis) discontinued participation
for personal reasons (largely because of
distance to study centers), rather than for
any medical reason.
In summary, we found that ingested
hrIFN- was a safe drug at the concentra-
tions used, and a beneﬁcial effect on
-cell function was observed in the
5,000-unit group. The long-term effects
of hrIFN- in type 1 diabetes are un-
known, and further studies are needed to
determine whether there is any sustained
beneﬁt.
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